Trial · NCT03123783
Participant flow70
How many started, completed or left each group, period by period.
21 to 40 of 70
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase 1b | Participants in the Efficacy Population | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 0 | |
| Phase 1b | COMPLETED | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b) | 3 | |
| Phase 1b | COMPLETED | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b) | 3 | |
| Phase 1b | COMPLETED | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b) | 0 | |
| Phase 1b | COMPLETED | Cohort 1(Arm)/ inNSCLC (Phase 2) | 0 | |
| Phase 1b | COMPLETED | Cohort 2(Arm)/ PD1-MM (Phase 2) - | 0 | |
| Phase 1b | COMPLETED | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 0 | |
| Phase 1b | COMPLETED | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 0 | |
| Phase 1b | NOT COMPLETED | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b) | 0 | |
| Phase 1b | NOT COMPLETED | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b) | 1 | |
| Phase 1b | NOT COMPLETED | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b) | 3 | |
| Phase 1b | NOT COMPLETED | Cohort 1(Arm)/ inNSCLC (Phase 2) | 0 | |
| Phase 1b | NOT COMPLETED | Cohort 2(Arm)/ PD1-MM (Phase 2) - | 0 | |
| Phase 1b | NOT COMPLETED | Cohort 3A(Arm)/ PD1-NSCLC (Phase 2) | 0 | |
| Phase 1b | NOT COMPLETED | Cohort 3B(Arm)/ PD1-NSCLC (Phase 2) | 0 | |
| Phase 2 | STARTED | DL1 - APX005M 0.03 mg/kg + Nivolumab (Phase 1b) | 0 | |
| Phase 2 | STARTED | DL2 - APX005M 0.1 mg/kg + Nivolumab (Phase 1b) | 0 | |
| Phase 2 | STARTED | DL3 - APX005M 0.3 mg/kg + Nivolumab (Phase 1b) | 0 | |
| Phase 2 | STARTED | Cohort 1(Arm)/ inNSCLC (Phase 2) | 53 | |
| Phase 2 | STARTED | Cohort 2(Arm)/ PD1-MM (Phase 2) - | 38 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123783/flow?page=2